Effect of Renal Disease on Pharmacokinetics and Bioavailability

  • Thomas P. Gibson


Therapeutically it is of vital importance to understand the pharmacokinetics and bioavailability of drugs, especially of those handled by the kidney. It would seem logical that with declining renal function, these functions might alter.


Renal Failure Normal Renal Function Absolute Bioavailability Slow Acetylators Renal Failure Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dettli L: Individualization of drug dosage in patients with renal disease. Med Clin North Am 58:977–985, 1974.PubMedGoogle Scholar
  2. 2.
    Dettli L, Spring P, Habersang R: Drug dosage in patients with impaired renal function. Postgrad Med J 46(suppl):32–35, 1970.CrossRefGoogle Scholar
  3. 3.
    Dettli L: Drug dosage in renal disease. Clin Pharmacokinet 1:126–134, 1976.PubMedCrossRefGoogle Scholar
  4. 4.
    Koch-Weser J: Pharmacokinetics of procainamide in man. Ann NY Acad Sci 179:370–382, 1971.PubMedCrossRefGoogle Scholar
  5. 5.
    Mark LC, Kayden HJ, Steele JM, Cooper JR, Berlin I, Rovenstine EA, Brodie BB: The physiological dispostion and cardiac effects of procainamide. J Pharmacol Exp Ther 102:5–15, 1951.PubMedGoogle Scholar
  6. 6.
    Gibson TP, Matusik J, Matusik E, Nelson HA, Wilkinson J, Briggs WA: Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype. Clin Pharmacol Ther 17:395–399, 1975.PubMedGoogle Scholar
  7. 7.
    Karlsson E, Molin L: Polymorphic acetylation of procainamide in healthy subjects. Acta Med Scand 197:299–302, 1975.PubMedCrossRefGoogle Scholar
  8. 8.
    Gibson TP, Lowenthal DT, Nelson HA, Briggs WA: Elimination of procainamide in end stage renal failure. Clin Pharmacol Ther 17:321–329, 1975.PubMedGoogle Scholar
  9. 9.
    Dreyfuss J, Bigger JT, Jr., Cohen AI, Schreiber EC: Metabolism of procainamide in rhesus monkey and man. Clin Pharmacol Ther 13:366–371, 1972.PubMedGoogle Scholar
  10. 10.
    Reidenberg MM, Drayer DE, Levy M, Warner H: Polymorphic acetylation of procainamide in man. Clin Pharmacol Ther 17:722–730, 1975.PubMedGoogle Scholar
  11. 11.
    Gibson TP, Atkinson AJ, Jr., Matusik E, Nelson LD, Briggs WA: Kinetics of procainamide and N-acetylprocainamide in renal failure. Kidney Int 12:422–429, 1977.PubMedCrossRefGoogle Scholar
  12. 12.
    Scott Em, Wright RC: Fluorometric determination of isonicotinic acid hydrazide in serum. J Lab Clin Med 70:355–360, 1967.PubMedGoogle Scholar
  13. 13.
    Matusik E, Gibson TP: Fluorometric assay for N-acetylprocainamide. Clin Chem 21:1899–1902, 1975.PubMedGoogle Scholar
  14. 14.
    Giardina EV, Dreyfuss J, Bigger JT, Shaw JM, Schreiber EC: Metabolism of procainamide in normal and cardiac subjects. Clin Pharmacol Ther 19:339–351, 1976.PubMedGoogle Scholar
  15. 15.
    Bowersox DW, Winterbauer RH, Stewart GL, Orme B, Barron E: Isoniazide dosage in patients with renal failure. N Engl J Med 289:84–87, 1973.PubMedCrossRefGoogle Scholar
  16. 16.
    Reidenberg MM, Shear L, Cohen RV: Elimination of isoniazide in patients with impaired renal function. Am Rev Resp Dis 108:1426–1428, 1973.PubMedGoogle Scholar
  17. 17.
    Dettli L, Spring P: in Okita GT, Acheson GH (eds): The Modifying Effects of Physiological Variables and Disease upon Pharmacokinetics—An Introduction. Basel, Karger, 1973, vol 3, pp 165–173.Google Scholar
  18. 18.
    Perrier D, Gibaldi M: Clearance and biologic half-life as indices of intrinsic hepatic metabolism. J Pharmacol Exp Ther 19:17–24, 1974.Google Scholar
  19. 19.
    Atkinson AJ, Jr., Lee W-K, Quinn ML, Cushner W, Nevin MJ, Strong JM: Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions. Clin Pharmacol Ther 21:575–587, 1977.PubMedGoogle Scholar
  20. 20.
    Lee W-K, Strong JM, Kehoe RF, Dutcher JS, Atkinson AJ, Jr.: Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions. Clin Pharmacol Ther 19:508–514, 1976.PubMedGoogle Scholar
  21. 21.
    Strong JM, Dutcher JS, Lee W-K, Atkinson AJ, Jr.: Pharmacokinetics in man of the N-acetylated metabolite of procainamide. J Pharmacokinet Biopharm 3:223–235, 1975.PubMedCrossRefGoogle Scholar
  22. 22.
    Stec GP, Atkinson AJ, Jr., Nevin MJ, Thenot J-P, Ruo TI, Gibson TP, Ivanovich P, del Greco F: N-acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis. Clin Pharmacol Ther 26:618–628, 1979.PubMedGoogle Scholar
  23. 23.
    Gibson TP, Matusik E, Briggs WA: N-acetylprocainamide levels in patients with end stage renal failure. Clin Pharmacol Ther 19:206–212, 1976.PubMedGoogle Scholar
  24. 24.
    Goldstein A, Aronow L, Kaiman SM: Principles of Drug Actions: The Basis of Pharmacology. New York, Wiley, 1975, p 324.Google Scholar
  25. 25.
    Elson J, Strong JM, Lee W-K, Atkinson AJ, Jr.: Antiarrhythmic potency of N-acetylprocainamide. Clin Pharmcol Ther 17:134–140, 1975.Google Scholar
  26. 26.
    Koch-Weser J, Klein SW: Procainamide dosage schedules, plasma concentrations, and clinical effects. JAMA 215:1454–1460, 1971.PubMedCrossRefGoogle Scholar
  27. 27.
    Dittert LW, Cressman WA, Kaplan SA, Riegelman S, Wagner JG: Guidelines for biopharmaceutical studies in man. Washington, D.C., American Pharmaceutical Association, Academy of Pharmaceutical Sciences, 1972, p 17.Google Scholar
  28. 28.
    Fordtran JS, Soergel HR, Ingelfinger FJ: Intestinal absorption of D-xylose in man. N Engl J Med 267:274–279, 1962.PubMedCrossRefGoogle Scholar
  29. 29.
    Christiansen PA, Kirsner JB, Ablaya J: D-xylose and its use in the diagnosis of malabsorptive states. Am J Med 27:443–453, 1959.PubMedCrossRefGoogle Scholar
  30. 30.
    Wyngaarden JB, Segal S, Foley JB: Physiological disposition and metabolic fate of infused pentoses in man. J Clin Invest 36:1395–1407, 1967.CrossRefGoogle Scholar
  31. 31.
    Butterworth CE, Perey-Santiago E, Martinez de Jesus J, Santiri R: Studies on the oral and parenteral administration of D-xylose. N Engl J Med. 261:157–161, 1959.PubMedCrossRefGoogle Scholar
  32. 32.
    Finlay JM, Hogarth J, Nightman KJR: A clinical evaluation of the D-xylose tolerance test. Ann Intern Med 61:411–422, 1964.PubMedGoogle Scholar
  33. 33.
    Hoeney MR, Culank LS, Montgomery RD, Sarmmous HG: Evaluation of xylose absorption as measured in blood and urine. A one hour blood xylose screening test in malabsorption. Gastroenterology 75:393–400, 1978.Google Scholar
  34. 34.
    Craig RM, Murphy P, Gibson TP, Quintanilla A, Chao GC, Cochrane C, Patterson A, Athinson AJ Jr.: Kinetic analysis of D-xylose absorption in normal subjects and in patients with chronic renal failure. J Lab Clin Med 101:496–506, 1893.Google Scholar
  35. 35.
    Roe JH, Rice EW: A photometric method for the determination of free pentoses in animal tissues. J Biol Chem 173:507–512, 1948.PubMedGoogle Scholar
  36. 36.
    Segal S, Foley JB: The metabolism of C14 labeled pentoses in man. J Clin Invest 38:407–413, 1959.PubMedCrossRefGoogle Scholar
  37. 37.
    Huguenin P, Cochet B, Balant L, Loizeau ED: Test d’absorption du D-xylose. Schweiz Med Wschr 108:206–214, 1978.PubMedGoogle Scholar
  38. 38.
    Quintanilla A, Craig R, Gibson T, Shambaugh G: Glucose metabolism in uremia. Am J Clin Nutr 33:1446–1450, 1980.PubMedGoogle Scholar
  39. 39.
    Tilstone WJ, Fine A: Furosemide kinetics in renal failure. Clin Pharmacol Ther 23:644–650, 1978.PubMedGoogle Scholar
  40. 40.
    Chau NP, Weiss YA, Safara ME, Lavene DE, Georges DR, Milliez PL: Pindolol availability in hypertensive patients with normal and impaired renal function. Clin Pharmacol Ther 22:505–510, 1977.PubMedGoogle Scholar
  41. 41.
    Simenhoff ML: Metabolism and toxicity of aliphatic amines. Kidney Int 7:5314–5317, 1975.Google Scholar
  42. 42.
    Toshes PP, King CE, Spivey JC, Lorenz E: Xylose catabolism in the experimental rat blind loop syndrome. Gastroenterology 74:691–697, 1978.Google Scholar
  43. 43.
    Wagner JC: Biopharmaceutics: Absorption aspects. J Pharm Sci 50:359–387, 1961.PubMedCrossRefGoogle Scholar
  44. 44.
    Grodstein G, Harrison A, Roberts C, Ippoliti A, Kopple J: Impaired gastric emptying in hemodialysis patients. Am Soc Neph 12:82A, 1979.Google Scholar
  45. 45.
    Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G: Pharmacokinetics of D-propoxyphine in anephric patients. Clin Pharmacol Ther 21:103, 1977.Google Scholar
  46. 46.
    Wood AJJ, Vestal RE, Spannath C, Stone WJ, Wilkinson GR, Shand DG: Propranolol disposition in renal failure. Clin Res 27:239A, 1979.Google Scholar
  47. 47.
    Galeazzi RL, Gugger M, Weidmann P: Beta blockade with pindolol: Differential cardiac and renal effects despite similar plasma kinetics in normal and uremic man. Kidney Int 15:661–668, 1979.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1985

Authors and Affiliations

  • Thomas P. Gibson
    • 1
    • 2
  1. 1.Section of Nephrology/Hypertension and Department of MedicineNorthwestern University Medical School, Northwestern Memorial HospitalUSA
  2. 2.Veterans Administration Lakeside Medical CenterChicagoUSA

Personalised recommendations